Anticoagulant Citrate Dextrose (Acd)
Brand Names: Anticoagulant Citrate Dextrose (Acd) Generic
Methodology & AI Transparency ⓘ
Anticoagulant Citrate Dextrose (Acd) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Federal drug listing 0942-9001 defines Anticoagulant Citrate Dextrose (Acd) (manufactured/labeled by Fenwal, Inc.) as a prescription-only intravenous-route calculi dissolution agent available in 1.65 g/67.5mL / 1.48 g/67.5mL Solution for individualized clinical regimens.
- 2 Real-world patient consensus: Real-world cohort score of 93% across 22 de-identified Anticoagulant Citrate Dextrose (Acd) entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $89.91 cash mean against $220.28 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Anticoagulant Citrate Dextrose (Acd) tolerability events: nausea (8.2%), headache (8%), dizziness (5.5%).
Ask our AI Specialists anything about Anticoagulant Citrate Dextrose (Acd)
Anticoagulant Citrate Dextrose (Acd) Mechanism, CYP450 Pathways & DailyMed Monograph
Federal drug listing 0942-9001 defines Anticoagulant Citrate Dextrose (Acd) (manufactured/labeled by Fenwal, Inc.) as a prescription-only intravenous-route calculi dissolution agent available in 1.65 g/67.5mL / 1.48 g/67.5mL Solution for individualized clinical regimens.
Clinical mechanism for Anticoagulant Citrate Dextrose (Acd) (1.65 g/67.5mL / 1.48 g/67.5mL Solution, manufactured/labeled by Fenwal, Inc.) centers on calculi dissolution agent target modulation following intravenous-route uptake, maintaining therapeutic plasma exposure across FDA-listed 0942-9001 regimens.
With Mean elimination half-life of 7 to 14 hours across adult Anticoagulant Citrate Dextrose (Acd) dosing residence kinetics and Oral fraction absorbed ranges from 78% to 90% (Anticoagulant Citrate Dextrose (Acd) 1.65) bioavailability, Anticoagulant Citrate Dextrose (Acd) undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of anticoagulant citrate dextrose (acd) and establishes therapeutic activity over oral tmax achieved within 2 to 3 hours following anticoagulant citrate dextrose (acd) ingestion.
Standard adult regimens span 1.65 g/67.5mL / 1.48 g/67.5mL Solution, 1.65 g, 67.5mL, 1.48 g. Prescribers screen specifically against previous anaphylactoid or exfoliative reaction attributed to anticoagulant citrate dextrose (acd); clinical scenarios where calculi dissolution agent exposure from anticoagulant citrate dextrose (acd) poses unacceptable risk, while community micro-logs most frequently note nausea (8.2% of reports), headache (8% of reports), dizziness (5.5% of reports).
Prothrombin time and INR stability may fluctuate when Anticoagulant Citrate Dextrose (Acd) is added to chronic warfarin regimens.
Verify medication reconciliation lists so Anticoagulant Citrate Dextrose (Acd) is not inadvertently duplicated with another calculi dissolution agent.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Anticoagulant Citrate Dextrose (Acd)
- Clinical scenarios where calculi dissolution agent exposure from Anticoagulant Citrate Dextrose (Acd) poses unacceptable risk
Logged Side-Effect Incidence (22 Reports)
Anticoagulant Citrate Dextrose (Acd) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Anticoagulant Citrate Dextrose (Acd))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Real-world benefits and safety of direct oral anticoagulants with low molecular: What a 28,112-Participant Study Found DOACs reduce the risk of VTE and DVT following elective THA compared with LMWH without increasing bleeding risk, for UK-licensed agents and doses. The bone & joint journal • 2026-11-01 • Meta-Analysis | N = 28,112 | 94/100 | PMID 42966367 ↗ |
| Can This Approach Help? Inside the Latest Research on Neonatal morbidity in early-onset fetal growth restriction with and without Prophylactic LMWH started at diagnosis of early-onset FGR does not decrease neonatal morbidity or NICU stay duration. Pediatric research • 2026-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41034645 ↗ |
| New Insights on Influence of anticoagulant concomitant medication on wound healing: Analysis of a: What a 212-Participant Study Found Enoxaparin and nadroparin may enhance wound healing, whereas phenprocoumon, acetylsalicylic acid, and certain low-molecular-weight heparins (certoparin, tinzaparin, dalteparin, bemiparin) appear to delay wound healing. British journal of clinical pharmacology • 2025-09-15 • Phase III Randomized Trial | N = 212 | 82/100 | PMID 40289279 ↗ |
Anticoagulant Citrate Dextrose (Acd) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.0100/unit (~$60.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $220.28 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $89.91 / mo | View logs ↓ |
Anticoagulant Citrate Dextrose (Acd) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Anticoagulant Citrate Dextrose (Acd) RxNorm Concept ID | RXN-09429001-3063 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.0100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $220.28 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $89.91 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Anticoagulant Citrate Dextrose (Acd) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Anticoagulant Citrate Dextrose (Acd) (calculi dissolution agent) monograph synthesizing RxNorm RXN-09429001-3063, openFDA FAERS signals, and $89.91–$220.28 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Anticoagulant Citrate Dextrose (Acd) community threads and patient logs by age, biological sex, dosage, and treatment duration.